scholarly journals SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

2021 ◽  
Vol 2 (4) ◽  
pp. 100151
Author(s):  
Marissa N. Lawrence ◽  
Rubii M. Tamen ◽  
Pablo Martinez ◽  
Alicia Sable-Hunt ◽  
Tony Addario ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Cell Free Dna ◽  
Free Dna ◽  
Remote Participation ◽  
Dna Genotyping

Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls

Lung Cancer ◽  
2015 ◽  
Vol 90 (1) ◽  
pp. 78-84 ◽  
Author(s):  
Shu Xia ◽  
Chiang-Ching Huang ◽  
Min Le ◽  
Rachel Dittmar ◽  
Meijun Du ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Early Stage ◽  
Cell Free Dna ◽  
Lung Cancers ◽  
Genomic Variations ◽  
Free Dna ◽  
Normal Controls

scholarly journals PATH-27. MUTATION DETECTION USING PLASMA CELL-FREE DNA IN CHILDREN WITH CENTRAL NERVOUS SYSTEM TUMORS

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii430-iii430
Author(s):  
Ross Mangum ◽  
Jacquelyn Reuther ◽  
Koel Sen Baksi ◽  
Ryan C Zabriskie ◽  
Ilavarasi Gandhi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Plasma Cell ◽  
Pediatric Patients ◽  
Cns Tumors ◽  
Cell Free Dna ◽  
Pilot Studies ◽  
Dna And Rna ◽  
Free Dna ◽  
Initial Cohort

Abstract BACKGROUND The role of plasma cell-free DNA (cfDNA) as a cancer biomarker for tracking treatment response and detecting early relapse has been well described for solid tumors outside the central nervous system (CNS). However, the presence of a blood-brain barrier complicates the application of plasma cfDNA analysis for patients with CNS malignancies. METHODS cfDNA was extracted from plasma of pediatric patients with CNS tumors utilizing a QIAmp® MinElute® kit and quantitated with Qubit 2.0 Fluorometer. Extensive genomic testing, including targeted DNA and RNA solid tumor panels, exome and transcriptome sequencing, as well as copy number array, was performed on matched tumor samples as part of the Texas KidsCanSeq study. An Archer® Reveal ctDNA28 NGS kit was then used for assaying the sensitivity of detecting tumor-specific mutations in the plasma of these patients. RESULTS A median of 10.7ng cfDNA/mL plasma (Interquartile range: 6.4 – 15.3) was extracted from 78 patients at time of study enrollment. Longitudinal samples from 24 patients exhibited a median yield of 7.7ng cfDNA/mL plasma (IQR: 5.9 – 9.1). An initial cohort of 6 patients was identified with 7 somatic variants covered by the Archer® Reveal kit. Four of seven mutations identified in matched tumor specimens were detected in patient plasma at variant allele frequencies ranging from 0.2–1%. CONCLUSIONS While challenging, detection of cfDNA in the plasma of pediatric patients with CNS tumors is possible and is being explored in a larger patient cohort along with pilot studies investigating cerebrospinal fluid as an additional source for tumor-specific cfDNA.

scholarly journals Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma

PLoS ONE ◽  
2020 ◽  
Vol 15 (4) ◽  
pp. e0232365 ◽  
Author(s):  
Michihito Tagawa ◽  
Naomi Tambo ◽  
Masaki Maezawa ◽  
Mizuki Tomihari ◽  
Ken-ichi Watanabe ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Urothelial Carcinoma ◽  
Plasma Cell ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Admission Cell Free DNA as a Prognostic Factor in Burns: Quantification by Use of a Direct Rapid Fluorometric Technique

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Yaron Shoham ◽  
Yuval Krieger ◽  
Zvi H. Perry ◽  
Gad Shaked ◽  
Alexander Bogdanov-Berezovsky ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Plasma Cell ◽  
Tissue Injury ◽  
Total Body Surface Area ◽  
Fluorometric Assay ◽  
Burn Patients ◽  
Cell Free Dna ◽  
Free Dna ◽  
Potential Marker ◽  
Spearman’S Correlation

Background. Despite great advances in the treatment of burn patients, useful prognostic markers are sparse. During the past years there has been increasing interest in circulating plasma cell free DNA as a potential marker for tissue injury. We have developed a rapid direct fluorescent assay for cell free DNA quantification that allows obtaining accurate, fast, and inexpensive measurements.Objective. To use this technique for measuring plasma cell free DNA levels in burn patients and to further explore the use of cell free DNA as a potential marker of patient outcome in burns.Methods. Cell free DNA levels obtained from 14 burn victims within 6 hours of injury and 14 healthy controls were quantified by a direct rapid fluorometric assay.Results. Patient admission cell free DNA levels were significantly elevated compared with that of controls (1797 ± 1523 ng/mL versus 374 ± 245 ng/mL,P=0.004). There are statistically significant correlations between cell free DNA admission levels and burn degree (Spearman’s correlation = 0.78,P=0.001), total body surface area (Spearman’s correlation = 0.61,P=0.02), and total burn volume (Spearman’s correlation = 0.64,P=0.014).Conclusions. Admission cell free DNA levels can serve as a prognostic factor in burns and future routine use can be made possible by use of our direct rapid fluorometric assay.

Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Oscar D. Pons-Belda ◽  
Amaia Fernandez-Uriarte ◽  
Annie Ren ◽  
Eleftherios P. Diamandis
Keyword(s):  
Plasma Cell ◽  
Cancer Detection ◽  
Prognostic Significance ◽  
Cell Free Dna ◽  
Free Dna
Sign in / Sign up

Export Citation Format

Share Document